BCM
LTRN icon

BIOS Capital Management’s Lantern Pharma LTRN Stock Holding History

BIOS Capital Management’s Portfolio LTRN Stock Details LTRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.04M Sell
249,397
-615,038
-71% -$1.8M 2.5% 5
2026
Q1 		$1.18M Sell
864,435
-145,072
-14% -$406K 2.24% 5
2025
Q4 		$3.06M Sell
1,009,507
-6,208
-0.6% -$23.1K 3.7% 4
2025
Q3 		$4.42M Sell
1,015,715
-60,237
-6% -$251K 4.97% 4
2025
Q2 		$3.4M Sell
1,075,952
-131,757
-11% -$445K 4.68% 3
2025
Q1 		$4.28M Hold
1,207,709
– – 5.4% 2
2024
Q4 		$3.85M Buy
+1,207,709
New +$4.14M 4.09% 4

Other funds holding LTRN

EAM
Empery Asset Management New York $86.5M AUM
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $33.6B AUM 31.03% 1-Year Est. Return

BIOS Capital Management's LTRN Position: Q2 2026 in Review

BIOS Capital Management reduced its Lantern Pharma (LTRN) stake by 71% in Q2 2026, selling an estimated $1.8M and leaving 249,397 shares worth $1.04M. The position accounts for 2.5% of the portfolio, ranked #5.

BIOS Capital Management first reported a position in LTRN in Q4 2024 and has held it in 7 quarters since. The position peaked at $4.42M in Q3 2025. 39 funds tracked by Wall St. Rank hold LTRN as of Q2 2026.

  • BIOS Capital Management held 249,397 shares of Lantern Pharma worth $1.04M as of Q2 2026.
  • BIOS Capital Management sold 615,038 Lantern Pharma shares in Q2 2026, an estimated $1.8M.
  • Lantern Pharma made up 2.5% of BIOS Capital Management's portfolio in Q2 2026, its #5 holding.
  • BIOS Capital Management first reported a position in Lantern Pharma in Q4 2024 and has held it in 7 quarters since.
  • BIOS Capital Management's Lantern Pharma position peaked at $4.42M in Q3 2025.
  • 39 funds tracked by Wall St. Rank held Lantern Pharma as of Q2 2026.

Based on BIOS Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.